ChemDiv, a global leader in drug discovery solutions, announced a strategic partnership with the University of Texas Medical Branch (UTMB) to expand its inventory and promote the institution's High-throughput Screening (HTS) research programs...
A collaboration with Miltenyi has been announced to develop and produce Cell BioEngines, Inc.'s expanded hematopoietic stem cell transplantation (HSCT) product for clinical use in hematology-oncology. Cell BioEngines, Inc. is a clinical-stage...
Venus Remedies has obtained Israeli commercial authorization for docetaxel and Colombian marketing authorization for cytarabine. While docetaxel, an antineoplastic drug, is effective in the treatment of breast, prostate, head and neck, and non...
In the dynamic landscape of pharmaceuticals, the integration of cleanroom technology stands out as a revolutionary force, supported by compelling research statistics. Recent industry studies unveil a staggering 90 percent reduction in airborne
Sanegene Bio USA Inc and Innovent Biologics, Inc. have announced a collaborative agreement to co-develop SGB-3908, a siRNA drug candidate targeting angiotensinogen (AGT) for hypertension management. Innovent also receives an exclusive option to...
Bristol Myers Squibb and RayzeBio, Inc. announced a formal merger agreement in which Bristol Myers Squibb will pay $62.50 per share in cash for RayzeBio, for a total equity value of approximately $4.1 billion, or $3.6 billion net of projected cash...
Aurobindo Pharma Ltd said that its wholly-owned subsidiary, Eugia Pharma Specialities Ltd, has acquired final permission from the US Food and Drug Administration to manufacture and market generic Posaconazole injection, which is used to prevent...
OliX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company and leading developer of RNAi therapeutics, announced that the Alfred Human Research Ethics Committee (HREC) has approved the company to conduct a phase 1 clinical trial of...
AstraZeneca announced a $1.2 billion acquisition of Gracell Biotechnologies as the Anglo-Swedish pharma firm expands its cell treatment ambitions and expands its footprint in China, the world's second-largest pharmaceuticals market. The cash...
Bristol Myers Squibb and neuroscience-focused Karuna Therapeutics, Inc announced a definitive merger agreement in which Bristol Myers Squibb will acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7...
, CDSCO.jpg)
